Organogenesis Holdings Inc (ORGO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $105.15M
Last updated: Nov 17, 2026 at 11:06 AM ET
Organogenesis Holdings Inc (ORGO) Earnings: Report Dates and Results
Organogenesis Holdings (ORGO) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Organogenesis Holdings reported EPS of -$0.25, below the -$0.17 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ORGO has an expected report date of Feb 24, 2027.
ORGO Earnings Call
The latest ORGO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, ORGO beat 19, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $45.46M, down 69.9% from $150.86M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.25 | -$0.17 | -$0.17 - -$0.17 | -47.06% | Miss | -238.9% | 1 | 0 up, 1 down | Nov 5, 2026 | $45.46M |
| Jun 30, 2026 | -$0.71 | -$0.35 | -$0.40 - -$0.30 | -102.86% | Miss | N/A | 2 | 0 up, 1 down | Aug 6, 2026 | $43.76M |
| Mar 31, 2026 | -$0.34 | -$0.29 | -$0.29 - -$0.29 | -17.24% | Miss | N/A | 1 | 0 up, 1 down | May 7, 2026 | $37.23M |
| Dec 31, 2025 | $0.31 | $0.22 | N/A | +43.72% | Beat | +368.3% | 1 | 1 up, 0 down | Feb 26, 2026 | $225.61M |
| Sep 30, 2025 | $0.18 | $0.07 | $0.07 - $0.07 | +157.14% | Beat | +80.0% | 1 | 0 up, 1 down | Nov 6, 2025 | $150.86M |
| Jun 30, 2025 | -$0.09 | -$0.01 | -$0.01 - -$0.01 | -800.00% | Miss | -325.0% | 1 | 0 up, 0 down | Aug 7, 2025 | $101.00M |
| Mar 31, 2025 | -$0.11 | -$0.03 | -$0.03 - -$0.03 | -266.67% | Miss | N/A | 1 | 0 up, 0 down | May 8, 2025 | $86.69M |
| Dec 31, 2024 | $0.07 | $0.02 | $0.02 - $0.02 | +231.00% | Beat | N/A | 1 | 0 up, 1 down | Feb 27, 2025 | $126.66M |
| Sep 30, 2024 | $0.10 | $0.02 | N/A | +400.00% | Beat | +150.0% | 4 | 0 up, 0 down | Nov 12, 2024 | $115.18M |
| Jun 30, 2024 | $0.04 | $0.02 | N/A | +100.00% | Beat | -20.0% | 4 | 0 up, 0 down | Aug 8, 2024 | $130.23M |
| Mar 31, 2024 | -$0.01 | -$0.03 | -$0.04 - -$0.01 | +66.67% | Beat | N/A | 3 | 0 up, 0 down | May 9, 2024 | $109.98M |
| Dec 31, 2023 | $0.00 | $0.01 | -$0.01 - $0.02 | -143.00% | Miss | -107.2% | 3 | 0 up, 0 down | Feb 29, 2024 | $99.65M |
| Sep 30, 2023 | $0.04 | $0.01 | $0.00 - $0.01 | +300.00% | Beat | 0.0% | 2 | 0 up, 0 down | Nov 9, 2023 | $108.53M |
| Jun 30, 2023 | $0.05 | $0.04 | N/A | +25.00% | Beat | -28.6% | 2 | 0 up, 0 down | Aug 9, 2023 | $117.32M |
| Mar 31, 2023 | -$0.01 | -$0.02 | -$0.02 - -$0.02 | +50.00% | Beat | -209.9% | 1 | 0 up, 0 down | May 10, 2023 | $107.64M |
| Dec 31, 2022 | $0.06 | $0.05 | $0.05 - $0.05 | +20.00% | Beat | -84.6% | 1 | 0 up, 0 down | Mar 1, 2023 | $115.52M |
| Sep 30, 2022 | $0.04 | $0.07 | N/A | -42.86% | Miss | -66.7% | 2 | 0 up, 0 down | Nov 9, 2022 | $116.86M |
| Jun 30, 2022 | $0.07 | $0.08 | N/A | -12.50% | Miss | -50.0% | N/A | 0 up, 0 down | Aug 9, 2022 | $121.40M |
| Mar 31, 2022 | $0.01 | $0.06 | $0.02 - $0.08 | -84.83% | Miss | -88.6% | 3 | 0 up, 0 down | May 10, 2022 | $97.12M |
| Dec 31, 2021 | $0.39 | $0.08 | $0.07 - $0.09 | +387.50% | Beat | +160.0% | 3 | 0 up, 0 down | Mar 1, 2022 | $127.86M |
| Sep 30, 2021 | $0.12 | $0.06 | $0.06 - $0.06 | +100.00% | Beat | -36.8% | 3 | N/A | Nov 9, 2021 | $113.75M |
| Jun 30, 2021 | $0.14 | $0.06 | $0.06 - $0.07 | +133.33% | Beat | N/A | 3 | N/A | Aug 9, 2021 | $123.20M |
| Mar 31, 2021 | $0.08 | -$0.02 | -$0.07 - $0.01 | +500.00% | Beat | N/A | 3 | N/A | May 10, 2021 | $102.55M |
| Dec 31, 2020 | $0.15 | $0.14 | $0.10 - $0.17 | +7.14% | Beat | N/A | 3 | N/A | Mar 16, 2021 | $106.81M |
| Sep 30, 2020 | $0.19 | -$0.07 | -$0.11 - -$0.06 | +371.43% | Beat | N/A | 4 | N/A | Nov 9, 2020 | $100.80M |
| Jun 30, 2020 | -$0.05 | -$0.26 | -$0.30 - -$0.12 | +80.77% | Beat | N/A | 4 | N/A | Aug 10, 2020 | $68.96M |
| Mar 31, 2020 | -$0.16 | -$0.13 | -$0.17 - -$0.11 | -23.08% | Miss | N/A | 4 | N/A | May 11, 2020 | $61.73M |
| Dec 31, 2019 | -$0.04 | -$0.09 | -$0.10 - -$0.08 | +55.56% | Beat | N/A | 4 | N/A | Mar 9, 2020 | $74.64M |
| Sep 30, 2019 | -$0.12 | -$0.12 | -$0.13 - -$0.12 | 0.00% | In line | -124.0% | 3 | N/A | Nov 12, 2019 | $64.27M |
| Jun 30, 2019 | -$0.11 | -$0.13 | -$0.13 - -$0.11 | +15.38% | Beat | -375.0% | 3 | N/A | Aug 9, 2019 | $64.95M |
| Mar 31, 2019 | -$0.15 | -$0.11 | -$0.13 - -$0.09 | -36.36% | Miss | N/A | 4 | N/A | May 10, 2019 | $57.12M |
| Dec 31, 2018 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 18, 2019 | $63.60M |
| Sep 30, 2018 | $0.50 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2018 | $50.77M |
| Jun 30, 2018 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 7, 2018 | $43.55M |
| Mar 31, 2018 | -$0.01 | N/A | N/A | N/A | N/A | -150.0% | N/A | N/A | May 10, 2018 | $35.53M |
| Dec 31, 2017 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 14, 2018 | $198.51M |
| Sep 30, 2017 | -$0.30 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 | N/A |
| Jun 30, 2017 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2017 | N/A |
| Mar 31, 2017 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2017 | N/A |
| Dec 31, 2016 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 28, 2017 | $61084 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.29, up 47.8% from the year before. It was -$0.02 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.29 | +47.8% |
| Dec 31, 2024 | $0.20 | +159.2% |
| Dec 31, 2023 | $0.08 | -57.7% |
| Dec 31, 2022 | $0.18 | -75.5% |
| Dec 31, 2021 | $0.73 | +461.5% |
| Dec 31, 2020 | $0.13 | N/A |
| Dec 31, 2019 | -$0.42 | -202.4% |
| Dec 31, 2018 | $0.41 | N/A |
| Dec 31, 2017 | -$0.45 | N/A |
| Dec 31, 2016 | -$0.02 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,036 | 5 | |
| 2026Q2 | Jun 30, 2026 | 4,132 | 5 | |
| 2026Q1 | Mar 31, 2026 | 3,457 | 4 | |
| 2025Q4 | Dec 31, 2025 | 3,289 | 4 | |
| 2025Q3 | Sep 30, 2025 | 3,217 | 5 | |
| 2025Q2 | Jun 30, 2025 | 3,593 | 5 | |
| 2025Q1 | Mar 31, 2025 | 5,257 | 6 | |
| 2024Q4 | Dec 31, 2024 | 4,190 | 6 |
2026Q3 Earnings Call
Opening remarks
Gary Gillheeney Sr. President, CEO, and Chair of the Board Thank you, operator, and welcome everyone to Organogenesis Holdings' third quarter 2026 earnings conference call. I am joined on the call today by Dave Francisco, our Chief Financial Officer. Let me start with a brief agenda of what we will cover during our prepared remarks. I will begin with a brief review of our results and key developments in the third quarter and in recent months. Dave will then provide you with an in-depth review of our third quarter financial results, our balance sheet and financial condition at quarter end, as well as our financial outlook for 2026, which we updated in our press release this afternoon. I will then provide you some closing comments before we open up the call for your questions. Beginning with a review of our results and key developments in Q3, our revenue results reflect the significant contraction and slow pace of recovery in the skin substitute market following the withdrawal of the LCD coverage policies for skin substitutes and CMS's published comments regarding discarded product in December of 2025. On balance, we were encouraged to see the operating environment improve from what we experienced during the second quarter, particularly as it relates to improving clinician confusion. Although net product revenue declined 70% year-over-year in the third quarter, our net product revenue increased 6% quarter-over-quarter in Q3. As a leader in the industry, we leveraged our most comprehensive portfolio across multiple FDA classifications, specifically the only biologic PMA-approved product, Apligraf, to enhance our market share position with an increase in volume on a quarter-over-quarter basis, outperforming the declines that have been reported across the industry. As discussed on our second quarter conference call, the competitive landscape has changed dramatically in the months following CMS's sweeping changes to payment policy. Distributor-driven competitors, high-priced amniotic players, and companies engaged in fraudulent practices have been substantially reduced. Many of the remaining players are diversifying away from wound care or exiting the category altogether. In this new market, customers are deciding which products and which partners they can trust, and they are deciding based on efficacy, outcomes, and evidence. That is the foundation Organogenesis was built on and the primary driver of the continued growth in market share we are achieving this year. These gains are broad-based, with Apligraf, PuraPly AM, Affinity, and NuShield all demonstrating meaningful improvement. That breadth tells us that customers are placing their confidence in our portfolio, not just a single product. We are also treating more patients, and utilization of our skin substitutes is increasing. Our team's commitment to our customers and their patients is paying dividends.
Frequently Asked Questions About ORGO
When is Organogenesis Holdings's next earnings date?
Organogenesis Holdings's next earnings report is expected for Feb 24, 2027.
Did ORGO beat earnings estimates last quarter?
No. Organogenesis Holdings reported EPS of -$0.25 for the quarter ended Sep 30, 2026, below the -$0.17 estimate by 47.06%.
What EPS do analysts expect from ORGO next quarter?
The consensus EPS estimate for Organogenesis Holdings for the quarter ending Dec 31, 2026 is -$0.13 from 4 analysts, with estimates from -$0.15 to -$0.12.
How often does ORGO beat earnings estimates?
Organogenesis Holdings beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -100.25%.
ORGO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts